Breakthrough Therapy designation is an FDA program that speeds up the development and review of a drug or biologic when early clinical data suggest it may work substantially better than existing treatments for a serious condition. It was created by the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012 and is codified in the Federal Food, Drug, and Cosmetic Act. Unlike orphan drug designation, which turns on how rare a disease is, Breakthrough Therapy designation turns on how promising the early clinical evidence looks against a serious condition — the two are evaluated on entirely different axes and a product can qualify for one, both, or neither.
What Breakthrough Therapy designation is
Breakthrough Therapy designation is a formal FDA status, requested by a drug’s sponsor and granted (or denied) by the relevant FDA review division, that is meant to get an especially promising investigational drug to patients faster by intensifying FDA’s involvement throughout development. It is one of FDA’s four expedited programs for serious conditions — alongside Fast Track, Accelerated Approval, and Priority Review — but it is the only one of the four defined specifically around preliminary clinical evidence of a large treatment effect, rather than around unmet medical need alone, a surrogate-endpoint approval pathway, or a shortened review clock for a completed application.
Eligibility criteria
FDA applies two conjunctive criteria: the drug must be intended to treat a serious condition, and preliminary clinical evidence must indicate that the drug may demonstrate substantial improvement over available therapies on at least one clinically significant endpoint. Both elements have to be satisfied — a serious condition alone is the (lower) bar for Fast Track, not Breakthrough Therapy.
“Preliminary clinical evidence”
The evidence has to come from actual clinical experience with the drug in humans — not solely nonclinical or mechanistic data — though it does not need to meet the standard required for marketing approval. Small early-phase studies, and sometimes even a well-documented case series, can support a request if the observed effect is large enough and the endpoint is clinically meaningful.
“Clinically significant endpoint”
FDA generally reads this as an endpoint measuring an effect on irreversible morbidity or mortality (IMM), or on symptoms representing serious consequences of the disease. It can also be satisfied by a surrogate or intermediate endpoint reasonably likely to predict clinical benefit, a pharmacodynamic biomarker effect strongly suggestive of a clinically meaningful benefit, or a significantly improved safety profile relative to available therapy paired with evidence of similar efficacy.
What the designation confers
A drug that receives Breakthrough Therapy designation gets everything Fast Track designation provides, plus additional, more intensive features:
- All Fast Track features — including eligibility for rolling review, where a sponsor can submit completed portions of a marketing application for FDA review before the full application is finished, rather than waiting to submit everything at once.
- Intensive FDA guidance on an efficient development program, beginning as early as Phase 1, with FDA input on trial design intended to generate the data needed to support approval as directly as possible.
- Organizational commitment — involvement of senior FDA managers and cross-disciplinary project leads assigned to the review team, rather than the review proceeding through the standard single-reviewer pathway alone.
- Eligibility for Priority Review and Accelerated Approval — Breakthrough Therapy designation does not automatically confer either, but a designated product that meets the separate criteria for those programs (a completed application addressing an unmet need for Priority Review; a surrogate or intermediate clinical endpoint reasonably likely to predict clinical benefit for Accelerated Approval) can qualify for them as well.
What it does not do: waive any requirement to demonstrate safety and effectiveness, guarantee eventual approval, or shorten the clinical trial program itself below what the data actually require. The designation changes how closely and how early FDA engages with the sponsor’s development plan — it does not change the evidentiary bar a marketing application ultimately has to clear.
How and when sponsors request it
The sponsor requests Breakthrough Therapy designation, typically as part of or as an amendment to an Investigational New Drug (IND) application, since the request has to point to real clinical data already generated under that IND. FDA guidance recommends requesting designation no later than the end-of-Phase 2 meeting, since much of the program’s value — early, intensive guidance on the development program — is most useful before pivotal-trial design is locked in, though a request can in principle be submitted at other points in development where the underlying clinical evidence supports it. FDA reviews a designation request within 60 days of receipt and will either grant or deny it; a denial does not preclude the sponsor from continuing development or from reapplying later if stronger evidence emerges.
Breakthrough Therapy vs. Orphan Drug designation
These two are frequently confused because both are development-stage FDA designations aimed at getting important treatments to patients faster, but they are evaluated on unrelated criteria and a sponsor can hold either, both, or neither for the same product. Orphan drug designation turns on disease prevalence — fewer than 200,000 people affected in the U.S. — plus a plausible scientific rationale, and its incentives are largely economic: a clinical-trial tax credit, a PDUFA fee waiver, a Pediatric Research Equity Act exemption, and eligibility for market exclusivity if the product is later approved. Breakthrough Therapy designation turns on the strength of early clinical evidence against a serious condition, regardless of how common or rare that condition is, and its benefit is procedural: closer, earlier FDA engagement with the development program itself. A drug for a rare cancer, for example, could easily hold both designations at once — qualifying for orphan status on prevalence grounds and for Breakthrough Therapy status on the strength of an early response-rate signal — without either designation depending on the other.
Breakthrough Therapy vs. Fast Track vs. Priority Review vs. Accelerated Approval
All four expedited programs address serious or life-threatening conditions, but each solves a different problem in development or review:
- Fast Track requires only that the drug address an unmet medical need for a serious condition — no preliminary evidence of a treatment effect is required, which makes it the easiest of the four to qualify for and often the first one a sponsor obtains.
- Breakthrough Therapy requires everything Fast Track requires, plus preliminary clinical evidence of substantial improvement over available therapy on a clinically significant endpoint, and adds the intensive-guidance and organizational-commitment features above.
- Accelerated Approval is a pathway that lets FDA approve a drug based on an effect on a surrogate or intermediate clinical endpoint reasonably likely to predict clinical benefit, with confirmatory trials required post-approval to verify the predicted benefit actually materializes.
- Priority Review shortens FDA’s goal timeframe for acting on a completed marketing application (historically to 6 months rather than the standard 10) — it affects the review clock for an application that is otherwise ready to submit, not the development program leading up to it.
A single product can accumulate several of these across its development, and Breakthrough Therapy designation is often the one that most directly shapes trial design decisions research administrators help operationalize at the site level.
Why this matters for research administration
For research administrators and clinical operations staff supporting a Breakthrough Therapy-designated trial, the practical effect shows up mostly in timeline and design volatility rather than in site-level paperwork: FDA’s intensive engagement with the sponsor can lead to protocol amendments, adaptive design changes, or accelerated enrollment targets on a shorter runway than a conventional Phase 2/3 program, which has direct implications for clinical trial patient recruitment planning and for the budget and cost-recovery modeling covered in the cost of running a clinical trial. Trial conduct itself is still governed by the same ICH E6(R3) Good Clinical Practice framework and informed consent requirements regardless of designation status — Breakthrough Therapy designation changes how fast and how closely FDA is engaged with the sponsor, not the standards a site’s trial conduct is held to. For the broader regulatory landscape this designation sits within, see the clinical research pillar page.
Frequently asked questions
What is the difference between Breakthrough Therapy designation and orphan drug designation?
Orphan drug designation is based on disease prevalence (fewer than 200,000 U.S. patients) and confers largely economic incentives. Breakthrough Therapy designation is based on the strength of preliminary clinical evidence for a serious condition, regardless of how rare it is, and confers more intensive FDA engagement during development. A product can hold both, either, or neither.
Does Breakthrough Therapy designation guarantee FDA approval?
No. It does not waive any requirement to demonstrate safety and effectiveness and does not guarantee the drug will ultimately be approved. It changes how early and how intensively FDA engages with the development program, not the evidentiary bar the marketing application eventually has to clear.
How long does FDA take to decide on a Breakthrough Therapy designation request?
FDA reviews designation requests within 60 days of receipt and either grants or denies the request.
When should a sponsor request Breakthrough Therapy designation?
It can be requested once sufficient preliminary clinical evidence exists, and FDA guidance recommends doing so no later than the end-of-Phase 2 meeting, since the program’s early, intensive development guidance is most valuable before pivotal-trial design is finalized.
Can a drug lose Breakthrough Therapy designation?
Yes. FDA can rescind the designation if later clinical data no longer support the basis on which it was granted, or if the development program no longer meets the criteria.
Is Breakthrough Therapy designation the same as Priority Review?
No. Priority Review shortens FDA’s review clock for a completed marketing application. Breakthrough Therapy designation is granted earlier, during development, and shapes the development program itself; a Breakthrough Therapy-designated product may separately qualify for Priority Review once its application is submitted, but the two are distinct programs with distinct criteria.
